The Bruton tyrosine kinase (BTK) inhibitor Acalabrutinib has shown some activity in refractory B-cell lymphoma but with limited durable response and a phase 1 trial is currently evaluating combination with AZD9150 as part of the PRISM study [219]. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.